The Technical AnalystExchange: OTC Sector: Healthcare Industry: Biotechnology
Pathfinder Cell Therapy, Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0000
America/New_York / 14 mar 2024 @ 11:22
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.0200 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | N/A |
| SharesOutstanding: | 20 014 mill |
| Avg Daily Volume: | 0 mill |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/14 | 3/14 | 4/14 | 1/15 | 2/15 | 3/15 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 136.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0001 - 0.0001 ( +/- 0.00%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0000 (0.00% ) |
| Volume | 0.0005 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PFND
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PFND
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.